Revvity's results for the fourth quarter show significant growth in their Diagnostics business, as well as a rebound in sales within the Life Sciences sector.
Revvity, Inc. (NYSE:RVTY) will hold its Q4 2024 Earnings Conference Call on January 31, 2025, at 8:00 AM ET. The call will feature company representatives including Steve Willoughby, Prahlad Singh, and Max Krakowiak, along with various participants from different financial institutions. The operator, Lydia, will welcome everyone to the call.
Revvity (RVTY) reported quarterly earnings of $1.42 per share, which is higher than the Zacks Consensus Estimate of $1.36 per share. This is an increase compared to earnings of $1.25 per share from the same period last year.
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) has announced its financial results for the fourth quarter and the entire year ending December 29, 2024. In the fourth quarter of 2024, the company reported GAAP earnings per share of $0.78, up from $0.64 in the same quarter last year. Additionally, GAAP revenue for the quarter reached $729 million, compared to $696 million during the same period last year.
Revvity (RVTY) has a strong track record of surprising with its earnings and currently has the right mix of factors that suggest it may exceed expectations in its upcoming quarterly report.
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. will introduce its innovative Phenologic.AI™ software at SLAS2025 in San Diego from January 27-29. This software aims to transform cellular imaging processes for Revvity's Harmony™ and Signals Image Artist™ packages by using pre-trained deep-learning models to analyze brightfield images, which enhances live cell analysis with an extra multiplexing channel and more efficient workflows. This major development broadens the capabilities of their existing tools.
Revvity plans to broaden the FDA-approved options for the EUROIMMUN range of ChLIA automation solutions to reach more patients.
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) has announced that it will share its financial results for the fourth quarter and the entire year of 2024 before the market opens on Friday, January 31, 2025. On the same day at 8:00 a.m. ET, the company will hold a conference call to discuss these results. The call will be led by Prahlad Singh, the president and CEO, along with Max Krakowiak, the CFO, and a live audio webcast will be available for those who want to listen.
RVTY has a solid range of products, which makes people feel positive about the stock.
Revvity, Inc. is a top company in life sciences and diagnostics, known for its varied sources of income and solid financial position, which makes it a safer choice in biopharma. With 80% of its revenue coming from consumables, services, and software, the company enjoys steady income and financial security. Additionally, it operates worldwide and has a total addressable market of over $60 billion, highlighting its great potential for growth.